Related to Published Studies Uphold Health Risk Concerns about GSK’s Type 2 Diabetes Drug

• Elan Bets $1B on Theravance/GSK Respiratory Drugs
  
• Gene Involved in Energy Consumption Is Epigenetically Modified in Type 2 Diabetics
  
• Researchers Identify Gene Variants Influencing Insulin/Glucose Regulation
  
• Researchers Find Mechanism for Cellular Dysfunction and Apoptosis in Type 2 Diabetes
  
• Role of Brain Insulin in Type 2 Diabetes Revealed
  
• Levels of Five Metabolites Linked to Type 2 Diabetes Risk
  
• Scientists Find miRNA Involved in Obesity-Induced Insulin Resistance
  
• Researchers Identify Brain Cell Protein as Potential Target for Obesity and Type 2 Diabetes
  
• Researchers Suggest Role for Hypothalamic PPAR-Gamma in Diabetes Drug-Related Weight Gain
  
• Researchers Identify HDACs as Potential Targets for Type 2 Diabetes
  
• Mice Studies Provide Insights on Contradictory Role of Insulin-Degrading Enzyme
  
• Scientists Trigger White Fat to Become Brown Fat-Like to Treat Obesty and Type 2 Diabetes
  
• EMA Recommends Cautious Prescribing of Takeda's Actos due to Bladder Cancer Risk
  
• Scientists Find High-Fat Diet Causes Beta Cell Dysfunction Leading to Type 2 Diabetes
  
• Role Identified for Cancer-Related Genetic Elements in Glucose Metabolism and Type 2 Diabetes
  
• "Open" Season at GSK
  
• Investigators Find Pathway that May Better Explain How Antidiabetics Like Avandia Work
  
• FDA Significantly Restricts Access to GSK’s Antidiabetic Avandia
  
• European Regulator Wants GSK’s Type 2 Diabetes Drug Pulled from the Market
  
• GSK Halts Enrollment for Postmarketing Avandia Trial as FDA Reviews Safety